BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
Rhea-AI Summary
Bioxytran (OTC: BIXT) completed a private placement on March 18, 2026, raising approximately $1.2 million. The company issued about 21,071,667 common shares at ~$0.055 per share and warrants to buy up to 19,750,001 shares at $0.12, five-year term.
The company said it will use net proceeds for working capital, development programs, and selected commercialization, including an A-SUQAR® dietary supplement launch expected this quarter.
AI-generated analysis. Not financial advice.
Positive
- $1.2M financing strengthens company liquidity
- 21,071,667 shares issued provides immediate capital
- Warrants for 19,750,001 shares offer potential future capital
- Proceeds earmarked for development programs and commercialization
- Near-term commercial push: A-SUQAR® launch expected this quarter
Negative
- Issuance of 21,071,667 shares causes equity dilution
- Up to 19,750,001 warrant shares may further dilute on exercise
- Securities unregistered; resale restrictions limit liquidity
News Market Reaction – BIXT
On the day this news was published, BIXT gained 7.73%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Financing strengthens balance sheet and supports advancement of key development initiatives
NEWTON, MA, March 20, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology company focused on developing therapies targeting hypoxia and viral diseases, today announced that it has completed a private placement financing on March 18, 2026, resulting in gross proceeds of approximately
In connection with the financing, the Company issued an aggregate of approximately 21,071,667 shares of its common stock at a purchase price of approximately
The securities were offered and sold in a private placement pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Regulation D promulgated thereunder. The securities have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
The Company intends to use the net proceeds from the financing for working capital and general corporate purposes, including advancing its development programs and supporting selected commercialization initiatives.
“This financing strengthens our balance sheet and supports the advancement of our clinical and development initiatives,” said David Platt, PhD, Chief Executive Officer of Bioxytran. “In parallel, we are beginning to translate our galectin-targeting platform into commercial opportunities, including the market introduction of A-SUQAR®, our plant-derived dietary supplement expected to launch this quarter. This dual-track approach allows us to pursue near-term commercialization while continuing to advance our higher-value pharmaceutical programs.”
The warrants issued in connection with the financing provide the potential for additional capital upon exercise, further supporting the Company’s long-term growth plans.
About Bioxytran, Inc.
Bioxytran, Inc. is a biotechnology company focused on the development of therapeutics targeting hypoxia-related conditions and galectin-targeting carbohydrate technologies, with applications across infectious viral diseases, metabolic health, and inflammation. The company leverages proprietary technologies to address significant unmet medical needs, with programs spanning pharmaceutical development and select commercial applications.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the use of proceeds, future development plans, anticipated commercialization activities, and potential warrant exercises. Actual results may differ materially from those projected due to various factors. Bioxytran undertakes no obligation to update these statements except as required by law.
For more information, please visit:
www.bioxytraninc.com
Investor Contact:
David Platt, PhD
CEO, Bioxytran, Inc.
617-484-1199
David.Platt@bioxytraninc.com
